Table 1.
Clinical characteristic of patients with breast cancer involved in the study
| Characyeristics | Numeber of cases | % |
|---|---|---|
| All (%) | 383 | 100.0 |
| Age | ||
| < 50 years | 124 | 32.4 |
| ≥ 50 years | 259 | 67.6 |
| Tumour size | ||
| T1 | 108 | 28.2 |
| T2 | 268 | 70.0 |
| T3 | 7 | 1.8 |
| Nodal status | ||
| N0 | 53 | 13.8 |
| N1 | 238 | 62.2 |
| N2 | 79 | 20.6 |
| N3 | 13 | 3.4 |
| Grade | ||
| G1 | 37 | 9.7 |
| G2 | 145 | 37.8 |
| G3 | 201 | 52.5 |
| Oestrogen receptor status | ||
| Positive | 280 | 73.1 |
| Negative | 103 | 26.9 |
| Progesterone receptor status | ||
| Positive | 263 | 68.7 |
| Negative | 120 | 31.3 |
| HER2 status | ||
| Overexpressing | 187 | 48.8 |
| Not overexpressing | 196 | 51.2 |
| Ki-67LIa | ||
| ≤ 19.7% | 101 | 26.4 |
| > 19.7% | 282 | 73.6 |
| Breast cancer immunophenotypesb | ||
| LA | 56 | 14.6 |
| LB HER2− | 92 | 24.1 |
| LB HER2+ | 125 | 32.6 |
| HER2+ | 59 | 15.4 |
| TN | 51 | 13.3 |
| HPV infection—nested PCR | ||
| Yes | 17 | 4.4 |
| No | 366 | 95.6 |
| HPV infection—qPCR | ||
| Yes | 2 | 0.5 |
| No | 381 | 99.5 |
| P16 immunoespression | ||
| Yes | 2 | 0.5 |
| No | 381 | 99.5 |
Ki-67LI Ki-67 labelling index, LA luminal A, LB luminal B, TN triple negative
aCut-off point from minimal P value method
bImmunophenotypes indicated on the basis of ER, PgR, HER2 and Ki-67 expression according to St. Gallen International Expert Consensus on The Primary Therapy of Early Breast Cancer 2013[26]